IMCR Immunocore Corp Company Short-Term Debt

Immunocore - graphic logo of issuer IMCR

Immunocore Holdings plc (IMCR) management has earned market trust through the successful launch of its first product. The company minimizes biotech risks by developing treatments for rare tumors with the support of pharmaceutical behemoths. This chart of share prices on GURU.Markets, where the indicator stands at 0.00, confirms the firm's pricing power driven by its unique ImmTAC technology, which provides exclusive access to ocular melanoma therapy.

IMCR immunocore.com Short-Term Debt (07/04/2022 - 11/01/2026)

Analytical breakdowns and data insights for company Immunocore Corp (IMCR)

- current quotes and average value forecast:
Price Chart Immunocore|IMCR - Average Forecast Price
- market capitalization data:
Market Value Immunocore Holdings|IMCR - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Immunocore|IMCR - Total Stockholders' Equity|Market Capitalization to Book Value Ratio immunocore.com|IMCR - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Immunocore Holdings plc|IMCR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Immunocore Holdings plc|IMCR - Aggregate Debt Obligations|Debts to Book Capitalization Immunocore Holdings|IMCR - Long-Term Debt Volume|Company Short-Term Debt Immunocore|Quick Liquidity immunocore.com
- earnings and multiples data:
IMCR - Net Income
General company analysis:Immunocore (IMCR)
Flagship merchandise of immunocore.com

For the long-term investor, the reliability of Immunocore Holdings plc (IMCR) is determined by its ability to fund R&D without the risk of default. This metric measures the volume of liabilities maturing within one year, assessing the reserve of operational liquidity. Analyzing the short-term debt value reveals whether stability is being maintained through excessive borrowing. For the biotech sector, where reagent utilization is strictly controlled, this confirms financial resilience. Low liabilities guarantee business development without the need for emergency asset liquidations.

Competitors of Immunocore Holdings plc

IBRX - Company Short-Term Debt|Short-Term Debt Janux Therapeutics Inc|Arcus Bio (RCUS) - Company Short-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Short-Term Debt|Company Short-Term Debt Tango Therapeutics|Short-Term Debt iovance.com IOVA|Company Short-Term Debts IMTX|Xencor Inc (XNCR) - Short-Term Indebtedness|Compass Bio - Company Current Liabilities|Replimune Inc. (REPL) - Short-Term Debt|LYEL: Company Current Liabilities|Company Short-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Short-Term Debts|CGEN - Short-Term Debt Volume|Company Short-Term Debt IO Biotech Corp|Company Current Liabilities Sutro Biopharma, Inc (STRO)|Company Short-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)